When the storm comes. Anxiety, depression, sleep disorders – why will non-psychiatrists face the pandemic of mental disorders? Case report
Article Sidebar
Main Article Content
Abstract
We live in difficult times. A patient with anxiety, sleep disorders, and symptoms of depression becomes a standard patient not only for psychiatrists, but doctors of a different specialty. Prescriptions for antidepressants are also issued by family doctors, internists, neurologists, cardiologists and other specialists. This shows the role of educating doctors of all specialties in the diagnosis and treatment of mental disorders. The article presents several typical cases of patients who come to the clinic for the diagnosis of somatic diseases, while the basis of the reported symptoms is mental. The text focuses on the role of the selection of an adequate dose of the drug and the form of its administration as factors determining effective treatment and good compliance.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Gambin M, Sękowski M, Woźniak-Prus M et al. Objawy depresji i lęku wśród Polaków w trakcie epidemii COVID-19. Raport z badań podłużnych. Uniwersytet Warszawski.
3. Lubrańska A. Życie w cieniu pandemii – psychologiczne konsekwencje w sferze pracy. Horyzonty Wychowania. 2021; 20(55): 27-36. http://doi.org/10.35765/hw.2099.
4. Raina P, Wolfson C, Griffith L et al. A longitudinal analysis of the impact of the COVID-19 pandemic on the mental health of middle-aged and older adults from the Canadian Longitudinal Study on Aging. Nat Aging. 2021; 1: 1137-47.
5. Małyszczak K, Pawłowski T. Zespoły lękowo-depresyjne. Patogeneza, obraz kliniczny i leczenie. Akademia Medyczna im. Piastów Śląskich we Wrocławiu, Wrocław 2007.
6. Stein DJ, Hollander E. Współchorobowość depresji i zaburzeń lękowych. Via Medica, Gdańsk 2004.
7. Arnow BA, Blasey C, Manber R et al. Dropouts versus completers among chronically depressed outpatients. J Affect Disord. 2007; 97: 197-202.
8. Jarema M, Wichniak A. Podstawy rozpoznawanie i leczenie wybranych zaburzeń snu – Biblioteka Czasopisma „Psychiatria”. Via Medica, Gdańsk 2017.
9. Amos T, Witt EA, Alphs L et al. Poster Presented at 29th Annual US Psychiatric & Mental Health Congress, October 21–24 2016; San Antonio, USA.
10. Amos TB, Tandon N, Levebrve P et al. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database. J Clin Psychiatry. 2018; 79(2): pii:17m11725. http://doi.org/10.4088/JCP.17m11725.
11. Jarema M, Dudek D, Landowski J et al. Trazodon: lek przeciwdepresyjny : mechanizm działania i miejsce w leczeniu depresji. Psychiatria Polska. 2011; 45(4), 611-25.
12. Shigemoto Y, Fujii Y, Shinomiya K et al. Participation of histaminergic H1 and noradrenergic alpha 1 receptors in orexin A-induced wakefulness in rats. Brain Res. 2004; 1023: 121-5.
13. Oberndorfer S, Saletu-Zychlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiol. 2000; 42: 69-81.
14. Le Bon O. Contribution of sleep research to the development of new antidepressants. Dialogues Clin Neurosci. 2005; 7: 305-13.
15. Landowski J. Wybór leku przeciwdepresyjnego. Dysk Depr. 2001; 10: 2-11.
16. Charakterystyka produktu leczniczego – trazodon.